Neurocrine biosciences presents new kinect®-hd data showing significant reduction in chorea across body regions with ingrezza® (valbenazine) capsules

Data reinforce the clinically meaningful impact of ingrezza in adults with huntington's disease chorea findings presented at the 2025 american association of neuroscience nurses neuroscience advanced practice provider symposium san diego , march 17, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) presented data from the kinect®-hd study showcasing significant improvements in chorea across body regions with once-daily ingrezza® (valbenazine) capsules in adults with huntington's disease. the post-hoc analysis was presented at the neuroscience advanced practice provider symposium hosted by the american association of neuroscience nurses in new orleans.
NBIX Ratings Summary
NBIX Quant Ranking